• Damora Therapeutics published a preclinical research presentation on DMR-001, an Fc-null, half-life optimized monoclonal antibody targeting mutant calreticulin in ET and MF.
• Program highlights included binding affinity of 0.074 nM for Type 1 del52 mutCALR, 0.31 nM for Type 2 ins5.
• Non-human primate PK half-life was 15 days, versus 3.1 days for a reference mutCALR antibody; expected Phase 1 dosing SC Q4W.
• Data showed internalization of surface mutCALR, inhibition of pSTAT1 signaling, reduced proliferation; no ADCC or CDC activity reported.
• A Phase 1/1b study in mutCALR-driven MPN patients is planned to initiate in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.